Latest news with #BoehringerIngelheim
Khaleej Times
5 days ago
- General
- Khaleej Times
UAE: Kids as young as 3 should learn how to spot a stroke, says doctor
Children as young as three and four should be taught how to recognise the symptoms of a stroke, according to a top doctor in the UAE. This could increase awareness about the disease and ensure that victims get treatment during the 'golden hour' that dramatically increases the chances of survival. 'It should be part of their curriculum in the school,' Dr Suhail Abdulla AlRukn, President of the MENA Stroke Organisation, told Khaleej Times. 'In kindergarten and primary school, they should teach signs and symptoms of a stroke because children could see their family members having one and can become heroes who help them get the right treatment. It can be part of their education to have one or two classes per year about the symptoms of a stroke. That message will then go directly and indirectly into the community and to every house.' Dr Suhail was speaking on the sidelines of an event to raise awareness about strokes — in partnership with Boehringer Ingelheim (BI). He said that it was important for people to remember the acronym BEFAST to recognise a stroke. 'Once these signs are spotted, an ambulance should be called by dialing 998,' he said. 'It is important that the person is taken to a stroke specialist centre in the UAE, so as not to waste time. Emergency responders will know which nearest hospital to transport the patient to.' Stay up to date with the latest news. Follow KT on WhatsApp Channels. Timely intervention The golden hour for a stroke is considered to be the first hour because if treatment is administered within that time, there is a higher chance of survival. However, Dr Suhail said that many people do not understand the urgency of it. 'Last week, I had a 59-year-old Indian stroke patient,' he said. 'Her sister came with her and when I outlined the plan, she said she had to call her brother-in-law and her sister's children to discuss the treatment and then take a decision. This doesn't work for a stroke patient.' He also highlighted that it was important to reduce the intake of salt to reduce the incidence of a stroke. 'Seventy per cent of stroke victims have high blood pressure,' he said. 'Salt is one of the reasons for high blood pressure. People should have only 1.2 grams per day, which is equal to one portion of a pizza.' He added that it was important for health authorities to highlight the amount of salt on labels of food items. Life saving treatment For Ahmed Nawazy, timely treatment is what made the difference between life and death. In 2017, the then 27-year-old had just moved to Dubai from his hometown in Egypt to join a company in a senior position. Within months of arriving, he suffered a stroke while bathing his seven and five-year-old daughters. 'My wife had seen her grandmother suffer a stroke, so she immediately knew what was happening,' he said. 'She called the ambulance and I was rushed to a stroke specialist hospital where I got life-saving treatment.' He said he got immense support from his company, who gave him extended sick leave and then lighter loads as he made a full recovery from the incident. Today, Ahmed is doing better than ever and has had a son since. 'It was the timely medical attention that helped me rebuild my life,' he said. According to Ousama Al Haj of BI, the company understood the importance of raising awareness. 'This year we're giving special focus to raising awareness because we brought a new medication to the UAE,' he said. 'We are empowering people to act, recover, and take action. In the case of a stroke, the earlier the intervention, the better it is.'
Cision Canada
26-05-2025
- Health
- Cision Canada
Empowering Canadians with type 2 diabetes: Program highlights the power of education and allied health Français
BURLINGTON, ON, May 26, 2025 /CNW/ - New outcomes from Boehringer Ingelheim Canada's Access for Health Education and Disease Management (AHEAD) program underscores the essential role that allied health professionals and disease management education play in the lives of Canadians living with type 2 diabetes (T2D). According to a 2025 survey, Boehringer's innovative national program, AHEAD, has helped patients become active partners in their care by improving their understanding and self-management of their own health conditions. "The program has been instrumental in enhancing patient education at our clinic. Having resources on-site, where patients are comfortable and familiar with the staff, has removed barriers to access and created a positive patient experience," said Dr. Matthew D'Mello, Community Family Physician at the Glazier Medical Clinic in Oshawa, Ontario. A survey of the participating allied healthcare professionals revealed that 97 per cent of respondents felt the AHEAD program addressed a specific gap or need, with patients reporting an 88 per cent improvement in their quality of life and a 92 per cent enhancement in disease management. AHEAD was implemented in over 70 primary and specialty care clinics across Canada for the duration of 2024, reaching about 3,200 patients. The program focused on optimizing disease management through guideline-directed medical therapy, seeking to improve health outcomes with the potential to reduce rehospitalization rates, and decrease emergency department visits. Educators offered culturally diverse, accessible support, allowing participants to receive care how and where it was most impactful for them. "I am grateful for the incredible opportunity provided by the AHEAD program. It has enabled me to educate patients about their diabetes focusing on self-management, setting realistic goals, identifying individual barriers, and offering solutions to positively impact their health journeys," said Mrudula Golla, a pharmacist and diabetes educator in Oshawa, Ontario "We are excited to see the implementation of the AHEAD program has succeeded in addressing the needs of people living with type 2 diabetes," says Dr. Rasha Eldesouky Abouelabbas, Vice President, Medical and Regulatory Affairs Boehringer Ingelheim Canada. "As a system collaborator, Boehringer is proud to continue investing in programs like AHEAD to address critical gaps in the healthcare system, making a meaningful impact in the lives of patients and the system as a whole." Boehringer Ingelheim (Canada) Ltd. Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. The Canadian headquarters of Boehringer Ingelheim was established in 1972 in Montreal, Quebec and is now located in Burlington, Ontario. Boehringer Ingelheim employs approximately 500 people across Canada. Learn more at
Yahoo
26-05-2025
- Health
- Yahoo
Empowering Canadians with type 2 diabetes: Program highlights the power of education and allied health
BURLINGTON, ON, May 26, 2025 /CNW/ - New outcomes from Boehringer Ingelheim Canada's Access for Health Education and Disease Management (AHEAD) program underscores the essential role that allied health professionals and disease management education play in the lives of Canadians living with type 2 diabetes (T2D). According to a 2025 survey, Boehringer's innovative national program, AHEAD, has helped patients become active partners in their care by improving their understanding and self-management of their own health conditions. "The program has been instrumental in enhancing patient education at our clinic. Having resources on-site, where patients are comfortable and familiar with the staff, has removed barriers to access and created a positive patient experience," said Dr. Matthew D'Mello, Community Family Physician at the Glazier Medical Clinic in Oshawa, Ontario. A survey of the participating allied healthcare professionals revealed that 97 per cent of respondents felt the AHEAD program addressed a specific gap or need, with patients reporting an 88 per cent improvement in their quality of life and a 92 per cent enhancement in disease management. AHEAD was implemented in over 70 primary and specialty care clinics across Canada for the duration of 2024, reaching about 3,200 patients. The program focused on optimizing disease management through guideline-directed medical therapy, seeking to improve health outcomes with the potential to reduce rehospitalization rates, and decrease emergency department visits. Educators offered culturally diverse, accessible support, allowing participants to receive care how and where it was most impactful for them. "I am grateful for the incredible opportunity provided by the AHEAD program. It has enabled me to educate patients about their diabetes focusing on self-management, setting realistic goals, identifying individual barriers, and offering solutions to positively impact their health journeys," said Mrudula Golla, a pharmacist and diabetes educator in Oshawa, Ontario "We are excited to see the implementation of the AHEAD program has succeeded in addressing the needs of people living with type 2 diabetes," says Dr. Rasha Eldesouky Abouelabbas, Vice President, Medical and Regulatory Affairs Boehringer Ingelheim Canada. "As a system collaborator, Boehringer is proud to continue investing in programs like AHEAD to address critical gaps in the healthcare system, making a meaningful impact in the lives of patients and the system as a whole." Boehringer Ingelheim (Canada) Ltd. Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. The Canadian headquarters of Boehringer Ingelheim was established in 1972 in Montreal, Quebec and is now located in Burlington, Ontario. Boehringer Ingelheim employs approximately 500 people across Canada. Learn more at SOURCE Boehringer Ingelheim Canada Ltd. View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23-05-2025
- Business
- Yahoo
OSE Immunotherapeutics Announces that its Partner Boehringer Ingelheim Will Present Early Clinical Evidence of Innate Immune Modulation and Anti-Tumor Activity via SIRPα Blockade in Two Ongoing Trials at ASCO 2025
OSE Immunotherapeutics Announces that its Partner Boehringer Ingelheim Will Present Early Clinical Evidence of Innate Immune Modulation and Anti-Tumor Activity via SIRPα Blockade in Two Ongoing Trials at ASCO 2025 BI 765063 in combination with programmed cell death-1 (PD1) inhibitor antibody ezabenlimab + cetuximab demonstrated a well-tolerated safety profile and potentially promising efficacy signals as second-line treatment in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Next generation SIRPα inhibitor BI 770371 was shown to be well tolerated alone and in combination with PD1 inhibitor ezabenlimab in a dose escalation trial in patients with advanced solid tumors. BI 770371 is currently being further investigated in a Phase 1b study in first-line patients with R/M HNSCC. Nantes, France, 23 May 2025 – OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE), today proudly announced that its partner Boehringer Ingelheim will present new clinical data from two early-stage trials targeting the signal regulatory protein α (SIRPα) innate immune checkpoint at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, May 30 - June 3, 2025, in Chicago, IL, USA. In a Phase 1b study conducted by Boehringer, its potential, first-in-class SIRPα monoclonal antibody, BI 765063, demonstrated a manageable safety profile as well as preliminary signs of immune activation and additive antitumor activity when combined with PD-1 inhibitor ezabenlimab and cetuximab in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).1 Additionally, in an open-label, Phase I trial conducted by Boehringer, its next-generation SIRPα monoclonal antibody, BI 770371, alone and in combination with the PD-1 inhibitor ezabenlimab, was shown to be well tolerated in patients with advanced solid tumors. There were no dose-limiting toxicities in either treatment arm, and the maximum tolerated dose was not reached in either group.2 'The preliminary results from these early-stage programs are encouraging and further strengthen Boehringer's robust immuno-oncology pipeline aimed at accelerating next-generation cancer therapies to address high unmet patient needs,' said Mike Akimov, Head of Medicine, Therapy Area Oncology at Boehringer Ingelheim. 'Boehringer is developing various complementary approaches to activate the immune system against cancer cells and SIRPα blockade paired with a PD-1 inhibitor is a promising strategy. We look forward to seeing if this dual activation may lead to a broader and more sustained anti-tumor response as the programs progress.' BI 765063 and BI 770371 are designed to block the 'don't eat me' signal that cancer cells use to hide from the immune system. By targeting SIRPα, these antibodies help immune cells like macrophages recognize and destroy tumor cells, bolstering the body's natural defenses.3 Both antibodies have been developed in partnership with OSE Immunotherapeutics, with Boehringer solely responsible for future clinical development and commercialization. Boehringer will move forward with the improved next generation SIRPα inhibitor antibody BI 770371, which will now be tested in a Phase 1b study. Presentation Details: Title: An Open-Label, Phase Ib Trial of the SIRPα Inhibitor BI 765063 in Combination with the PD-1 Inhibitor Ezabenlimab and Cetuximab in Patients (pts) with Head and Neck Squamous Cell Carcinoma Abstract Number: 6019Session Type/Title: Rapid Oral Abstract – Developmental Therapeutics – ImmunotherapyDate/Time: 01 June 2025 – 11:30am – 1:30pm CDT Title: An Open-label, Phase I Trial of the SIRPα Monoclonal Antibody, BI 770371, Alone and in Combination with the PD-1 Inhibitor Ezabenlimab in Patients with Advanced Solid TumorsAbstract Number: 2515Session Type/Title: Rapid Oral Abstract – Developmental Therapeutics – ImmunotherapyDate/Time: 01 June 2025 – 11:15am – 12:45pm CDT Boehringer Ingelheim Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer Ingelheim takes a long-term perspective, embedding sustainability along the entire value chain. More than 54,400 employees serve over 130 markets to build a healthier, more sustainable and equitable tomorrow. Learn more at (Global). OSE ImmunotherapeuticsOSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs of today and tomorrow. We partner with leading academic institutions and biopharmaceutical companies in our efforts to develop and bring to the market transformative medicines for people with serious diseases. OSE Immunotherapeutics is based between Nantes and Paris and is quoted on Euronext. Additional information about OSE Immunotherapeutics assets is available on the Company's website: Click and follow us on LinkedIn. Contacts Boehringer Ingelheim Linda Ruckel+1 Reinhard Malin+49 (6132) OSE ImmunotherapeuticsFiona Dé French Media Contact FP2COMFlorence Portejoiefportejoie@ 6 07 768 283 U.S. Media ContactRooney Partners LLCKate Barrettekbarrette@ 212 223 0561 Forward-looking statementsThis press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics' management considering its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate. These forward-looking statements include statements typically using conditional and containing verbs such as 'expect', 'anticipate', 'believe', 'target', 'plan', or 'estimate', their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics' shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on April 30, 2025, including the annual financial report for the fiscal year 2024, available on the OSE Immunotherapeutics' website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements. 1 Link to the abstract2 Link to the abstract 3 Lopez-Yrigoyen, M., et al. (2017). Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity. Proceedings of the National Academy of Sciences, 114(33), 201710877. Attachment EN_250523_ASCO BI_OSE_vfError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23-05-2025
- Business
- Yahoo
OSE Immunotherapeutics Announces that its Partner Boehringer Ingelheim Will Present Early Clinical Evidence of Innate Immune Modulation and Anti-Tumor Activity via SIRPα Blockade in Two Ongoing Trials at ASCO 2025
OSE Immunotherapeutics Announces that its Partner Boehringer Ingelheim Will Present Early Clinical Evidence of Innate Immune Modulation and Anti-Tumor Activity via SIRPα Blockade in Two Ongoing Trials at ASCO 2025 BI 765063 in combination with programmed cell death-1 (PD1) inhibitor antibody ezabenlimab + cetuximab demonstrated a well-tolerated safety profile and potentially promising efficacy signals as second-line treatment in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Next generation SIRPα inhibitor BI 770371 was shown to be well tolerated alone and in combination with PD1 inhibitor ezabenlimab in a dose escalation trial in patients with advanced solid tumors. BI 770371 is currently being further investigated in a Phase 1b study in first-line patients with R/M HNSCC. Nantes, France, 23 May 2025 – OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE), today proudly announced that its partner Boehringer Ingelheim will present new clinical data from two early-stage trials targeting the signal regulatory protein α (SIRPα) innate immune checkpoint at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, May 30 - June 3, 2025, in Chicago, IL, USA. In a Phase 1b study conducted by Boehringer, its potential, first-in-class SIRPα monoclonal antibody, BI 765063, demonstrated a manageable safety profile as well as preliminary signs of immune activation and additive antitumor activity when combined with PD-1 inhibitor ezabenlimab and cetuximab in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).1 Additionally, in an open-label, Phase I trial conducted by Boehringer, its next-generation SIRPα monoclonal antibody, BI 770371, alone and in combination with the PD-1 inhibitor ezabenlimab, was shown to be well tolerated in patients with advanced solid tumors. There were no dose-limiting toxicities in either treatment arm, and the maximum tolerated dose was not reached in either group.2 'The preliminary results from these early-stage programs are encouraging and further strengthen Boehringer's robust immuno-oncology pipeline aimed at accelerating next-generation cancer therapies to address high unmet patient needs,' said Mike Akimov, Head of Medicine, Therapy Area Oncology at Boehringer Ingelheim. 'Boehringer is developing various complementary approaches to activate the immune system against cancer cells and SIRPα blockade paired with a PD-1 inhibitor is a promising strategy. We look forward to seeing if this dual activation may lead to a broader and more sustained anti-tumor response as the programs progress.' BI 765063 and BI 770371 are designed to block the 'don't eat me' signal that cancer cells use to hide from the immune system. By targeting SIRPα, these antibodies help immune cells like macrophages recognize and destroy tumor cells, bolstering the body's natural defenses.3 Both antibodies have been developed in partnership with OSE Immunotherapeutics, with Boehringer solely responsible for future clinical development and commercialization. Boehringer will move forward with the improved next generation SIRPα inhibitor antibody BI 770371, which will now be tested in a Phase 1b study. Presentation Details: Title: An Open-Label, Phase Ib Trial of the SIRPα Inhibitor BI 765063 in Combination with the PD-1 Inhibitor Ezabenlimab and Cetuximab in Patients (pts) with Head and Neck Squamous Cell Carcinoma Abstract Number: 6019Session Type/Title: Rapid Oral Abstract – Developmental Therapeutics – ImmunotherapyDate/Time: 01 June 2025 – 11:30am – 1:30pm CDT Title: An Open-label, Phase I Trial of the SIRPα Monoclonal Antibody, BI 770371, Alone and in Combination with the PD-1 Inhibitor Ezabenlimab in Patients with Advanced Solid TumorsAbstract Number: 2515Session Type/Title: Rapid Oral Abstract – Developmental Therapeutics – ImmunotherapyDate/Time: 01 June 2025 – 11:15am – 12:45pm CDT Boehringer Ingelheim Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer Ingelheim takes a long-term perspective, embedding sustainability along the entire value chain. More than 54,400 employees serve over 130 markets to build a healthier, more sustainable and equitable tomorrow. Learn more at (Global). OSE ImmunotherapeuticsOSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs of today and tomorrow. We partner with leading academic institutions and biopharmaceutical companies in our efforts to develop and bring to the market transformative medicines for people with serious diseases. OSE Immunotherapeutics is based between Nantes and Paris and is quoted on Euronext. Additional information about OSE Immunotherapeutics assets is available on the Company's website: Click and follow us on LinkedIn. Contacts Boehringer Ingelheim Linda Ruckel+1 Reinhard Malin+49 (6132) OSE ImmunotherapeuticsFiona Dé French Media Contact FP2COMFlorence Portejoiefportejoie@ 6 07 768 283 U.S. Media ContactRooney Partners LLCKate Barrettekbarrette@ 212 223 0561 Forward-looking statementsThis press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics' management considering its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate. These forward-looking statements include statements typically using conditional and containing verbs such as 'expect', 'anticipate', 'believe', 'target', 'plan', or 'estimate', their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics' shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on April 30, 2025, including the annual financial report for the fiscal year 2024, available on the OSE Immunotherapeutics' website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements. 1 Link to the abstract2 Link to the abstract 3 Lopez-Yrigoyen, M., et al. (2017). Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity. Proceedings of the National Academy of Sciences, 114(33), 201710877. Attachment EN_250523_ASCO BI_OSE_vfError while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
